Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HENRY SCHEIN INCHSIC · Entity 3536 | President, Global Medical Grp | March 06, 2017 | March 08, 2017 |
| LEMAITRE VASCULAR INCLMAT · Entity 1927 | Director | May 07, 2026 | May 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HENRY SCHEIN INC
Report date March 06, 2017 · Filed March 08, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per shareSEC Table I · non-derivative | Direct | 9,654 |
Reported balance
After 2017-03-06 transaction · row 1
1 source rowRow 1 · 2017-03-06 · Grant · Acquired 9,654 · Balance 9,654 F1: Grant of restricted stock (RS) pursuant to the Issuer's 2013 Stock Incentive Plan. Subject to certain exceptions, 65% will vest subject to (x) Issuer's achievement of a specified performance goal and (y) reporting person's continued perf. of services for the Issuer. 35% will vest subject to (x) passage of a specified period of time and (y) reporting person's continued perf. of services for the Issuer. With respect to the performance-based RS, if the continued service requirement is satisfied and achievement of the performance goal (x) exceeds 100% of target, the Issuer may issue additional vested shares of common stock in an amount that corresponds to the incremental percentage of the performance goal achieved in excess of 100% of target or (y) is less than 100% of target, the reporting person will surrender to the Issuer shares of common stock in an amount that corresponds to the incremental percentage of the performance goal achieved that is below 100% of target (i.e., shortfall). |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock (RS) pursuant to the Issuer's 2013 Stock Incentive Plan. Subject to certain exceptions, 65% will vest subject to (x) Issuer's achievement of a specified performance goal and (y) reporting person's continued perf. of services for the Issuer. 35% will vest subject to (x) passage of a specified period of time and (y) reporting person's continued perf. of services for the Issuer. With respect to the performance-based RS, if the continued service requirement is satisfied and achievement of the performance goal (x) exceeds 100% of target, the Issuer may issue additional vested shares of common stock in an amount that corresponds to the incremental percentage of the performance goal achieved in excess of 100% of target or (y) is less than 100% of target, the reporting person will surrender to the Issuer shares of common stock in an amount that corresponds to the incremental percentage of the performance goal achieved that is below 100% of target (i.e., shortfall).
LEMAITRE VASCULAR INC
Report date May 07, 2026 · Filed May 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,942 |
Ending reported balance
After 2026-05-07 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-05-07 · Exercise / conversion · Acquired 3,444 · Balance 7,386 F1: Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II. Row 2 · 2026-05-07 · Exercise / conversion · Acquired 1,600 · Balance 8,986 F1: Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II. Row 3 · 2026-05-07 · Sale · Disposed 5,044 · Balance 3,942 F2: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $111.00 to $111.30. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.60 · Expires 2026-12-11 | Direct | 0 |
Reported balance
After 2026-05-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-07 · Exercise / conversion · Disposed 3,444 · Balance 0 F3: This option is fully vested and exercisable. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.19 · Expires 2027-12-12 | Direct | 1,609 |
Reported balance
After 2026-05-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-07 · Exercise / conversion · Disposed 1,600 · Balance 1,609 F3: This option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II.
F2: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $111.00 to $111.30. The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected.
F3: This option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 02, 2023 Filed Jun 5, 2023 21:08 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | SaleCommon Stock | 5,000 | $64.24 | $321,200.00 |
DisclosureSEC source: 0001437749-23-016659 · rdgdoc.xml · nonDerivative · entry 2 Ross Bridget A · CIK 0001698518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,169 F2 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $64.23 to $64.44. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected. Read SEC document |
| June 02, 2023 Filed Jun 5, 2023 21:08 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | Exercise / conversionCommon Stock | 5,000 | $37.29 | $186,450.00 |
DisclosureSEC source: 0001437749-23-016659 · rdgdoc.xml · nonDerivative · entry 1 Ross Bridget A · CIK 0001698518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,169 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:29 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | GrantDividend Equivalent Rights · Derivative | 1.2968 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-016642 · rdgdoc.xml · derivative · entry 2 Ross Bridget A · CIK 0001698518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2.96 Underlying: Common Stock · 1.2968 shares Expires not disclosed F2 · derivative.exercise_price: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. F2 · derivative.exercise_date: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. F2 · derivative.expiration_date: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 20:29 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | GrantDividend Equivalent Rights · Derivative | 0.8464 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-016642 · rdgdoc.xml · derivative · entry 1 Ross Bridget A · CIK 0001698518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6.46 Underlying: Common Stock · 0.8464 shares Expires not disclosed F1 · derivative.exercise_price: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. F1 · derivative.exercise_date: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. F1 · derivative.expiration_date: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 12:26 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | GrantDividend Equivalent Rights · Derivative | 1.6595 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-007967 · rdgdoc.xml · derivative · entry 2 Ross Bridget A · CIK 0001698518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1.6595 Underlying: Common Stock · 1.6595 shares Expires not disclosed F2 · derivative.exercise_price: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. F2 · derivative.exercise_date: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. F2 · derivative.expiration_date: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. Read SEC document |
| March 23, 2023 Filed Mar 27, 2023 12:26 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | GrantDividend Equivalent Rights · Derivative | 1.083 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-007967 · rdgdoc.xml · derivative · entry 1 Ross Bridget A · CIK 0001698518 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5.6094 Underlying: Common Stock · 1.083 shares Expires not disclosed F1 · derivative.exercise_price: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. F1 · derivative.exercise_date: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. F1 · derivative.expiration_date: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:40 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $30.00 Strike: $30.00 | $210,000.00 |
DisclosureSEC source: 0001437749-23-005099 · rdgdoc.xml · derivative · entry 3 Ross Bridget A · CIK 0001698518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 7,000 shares Expires 2025-04-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is exercisable and vests over a three-year period at a rate of 33 1/3% on the first anniversary of the date listed in the table, with the balance vesting in equal annual installments over the remaining two years. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:40 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | SaleCommon Stock | 7,000 | $49.27 | $344,890.00 |
DisclosureSEC source: 0001437749-23-005099 · rdgdoc.xml · nonDerivative · entry 2 Ross Bridget A · CIK 0001698518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,183 F2 · price: The price reported in Column 4 is a weighted average price. The transaction was executed in multiple trades ranging from $49.03 to $49.78 The reporting person undertakes to provide to the issuer, any securityholder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares and price at which the transaction was effected. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:40 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | Exercise / conversionCommon Stock | 7,000 | $30.00 | $210,000.00 |
DisclosureSEC source: 0001437749-23-005099 · rdgdoc.xml · nonDerivative · entry 1 Ross Bridget A · CIK 0001698518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,183 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II. Read SEC document |
| December 12, 2022 Filed Dec 13, 2022 22:29 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | GrantStock Option (Right to Buy) · Derivative | 3,209 | $0.00 Strike: $47.19 | $0.00 |
DisclosureSEC source: 0001437749-22-028999 · rdgdoc.xml · derivative · entry 2 Ross Bridget A · CIK 0001698518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,209 Underlying: Common Stock · 3,209 shares Expires 2027-12-12 F2 · derivative.exercise_date: This option is exercisable and vests over a three-year period at a rate of 33 1/3% on the first anniversary of the date listed in the table, with the balance vesting in equal annual installments over the remaining two years. Read SEC document |
| December 12, 2022 Filed Dec 13, 2022 22:29 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | GrantCommon Stock | 593 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-028999 · rdgdoc.xml · nonDerivative · entry 1 Ross Bridget A · CIK 0001698518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,169 F1 · shares: Represents a restricted stock unit award that vests on a time-based schedule as follows: 33 1/3% of the award vests on the anniversary of the grant date listed in the table, with the balance vesting in equal annual installments over the remaining two years. Read SEC document |
| December 01, 2022 Filed Dec 6, 2022 01:15 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | GrantDividend Equivalent Rights · Derivative | 1.5264 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-028472 · rdgdoc.xml · derivative · entry 1 Ross Bridget A · CIK 0001698518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4.5264 Underlying: Common Stock · 1.5264 shares Expires not disclosed F1 · derivative.exercise_price: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. F1 · derivative.exercise_date: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. F1 · derivative.expiration_date: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 20:56 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | GrantDividend Equivalent Rights · Derivative | 1 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-022221 · rdgdoc.xml · derivative · entry 1 Ross Bridget A · CIK 0001698518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3 Underlying: Common Stock · 1 shares Expires not disclosed F1 · derivative.exercise_price: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. F1 · derivative.exercise_date: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. F1 · derivative.expiration_date: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 20:33 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | GrantDividend Equivalent Rights · Derivative | 1 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-014414 · rdgdoc.xml · derivative · entry 1 Ross Bridget A · CIK 0001698518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2 Underlying: Common Stock · 1 shares Expires not disclosed F1 · derivative.exercise_price: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. F1 · derivative.exercise_date: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. F1 · derivative.expiration_date: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. Read SEC document |
| March 24, 2022 Filed Mar 29, 2022 01:04 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | GrantDividend Equivalent Rights · Derivative | 1 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-007475 · rdgdoc.xml · derivative · entry 1 Ross Bridget A · CIK 0001698518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1 Underlying: Common Stock · 1 shares Expires not disclosed F1 · derivative.exercise_price: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. F1 · derivative.exercise_date: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. F1 · derivative.expiration_date: These dividend equivalent rights accrued on a restricted stock unit award granted on 12/11/2021 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock. Read SEC document |
| December 11, 2021 Filed Dec 14, 2021 21:06 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | GrantStock Option (Right to Buy) · Derivative | 3,444 | $0.00 Strike: $48.60 | $0.00 |
DisclosureSEC source: 0001437749-21-028542 · rdgdoc.xml · derivative · entry 2 Ross Bridget A · CIK 0001698518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,444 Underlying: Common Stock · 3,444 shares Expires 2026-12-11 F2 · derivative.exercise_date: This option is exercisable and vests over a three-year period at a rate of 33 1/3% on the first anniversary of the date listed in the table, with the balance vesting in equal annual installments over the remaining two years. Read SEC document |
| December 11, 2021 Filed Dec 14, 2021 21:06 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | GrantCommon Stock | 576 | $48.60 | $27,993.60 |
DisclosureSEC source: 0001437749-21-028542 · rdgdoc.xml · nonDerivative · entry 1 Ross Bridget A · CIK 0001698518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 576 F1 · shares: Represents a restricted stock unit award that vests on a time-based schedule as follows: 33 1/3% of the award vests on the anniversary of the grant date listed in the table, with the balance besting in equal annual installments over the remaining two years. This award includes a provision for the withholding of shares by the issuer to pay the withholding taxes due upon each vesting date. Read SEC document |
| December 02, 2020 Filed Dec 5, 2020 00:46 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $37.29 | $0.00 |
DisclosureSEC source: 0001437749-20-024905 · rdgdoc.xml · derivative · entry 1 Ross Bridget A · CIK 0001698518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2025-12-02 F1 · derivative.exercise_date: This option is exercisable and vests over a three-year period at a rate of 33 1/3% on the first anniversary of the date listed in the table, with the balance vesting in equal annual installments over the remaining two years. Read SEC document |
| May 19, 2020 Filed May 22, 2020 01:41 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001437749-20-011596 · rdgdoc.xml · derivative · entry 3 Ross Bridget A · CIK 0001698518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2025-04-28 F2 · derivative.exercise_date: This option is exercisable and vests over a three-year period at a rate of 33 1/3% on the first anniversary of the date listed in the table, with the balance vesting in equal annual installments over the remaining two years. Read SEC document |
| May 19, 2020 Filed May 22, 2020 01:41 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | OtherStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001437749-20-011596 · rdgdoc.xml · derivative · entry 2 Ross Bridget A · CIK 0001698518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2025-04-28 F3 · kind: Rescission of stock option by compensation committee prior to acceptance of grant F2 · derivative.exercise_date: This option is exercisable and vests over a three-year period at a rate of 33 1/3% on the first anniversary of the date listed in the table, with the balance vesting in equal annual installments over the remaining two years. Read SEC document |
| April 28, 2020 Filed May 22, 2020 01:41 UTC | LEMAITRE VASCULAR INC LMAT · Entity 1927 | OtherStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $30.00 | $0.00 |
DisclosureSEC source: 0001437749-20-011596 · rdgdoc.xml · derivative · entry 1 Ross Bridget A · CIK 0001698518 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2025-04-28 F1 · kind: Grant of stock option by compensation committee F2 · derivative.exercise_date: This option is exercisable and vests over a three-year period at a rate of 33 1/3% on the first anniversary of the date listed in the table, with the balance vesting in equal annual installments over the remaining two years. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 22:29 UTC | HENRY SCHEIN INC HSIC · Entity 3536 | GrantCommon Stock, par value $0.01 per share | 9,654 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-019345 · doc4.xml · nonDerivative · entry 1 Ross Bridget A · CIK 0001698518 · President, Global Medical Grp 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,654 F1 · shares: Grant of restricted stock (RS) pursuant to the Issuer's 2013 Stock Incentive Plan. Subject to certain exceptions, 65% will vest subject to (x) Issuer's achievement of a specified performance goal and (y) reporting person's continued perf. of services for the Issuer. 35% will vest subject to (x) passage of a specified period of time and (y) reporting person's continued perf. of services for the Issuer. With respect to the performance-based RS, if the continued service requirement is satisfied and achievement of the performance goal (x) exceeds 100% of target, the Issuer may issue additional vested shares of common stock in an amount that corresponds to the incremental percentage of the performance goal achieved in excess of 100% of target or (y) is less than 100% of target, the reporting person will surrender to the Issuer shares of common stock in an amount that corresponds to the incremental percentage of the performance goal achieved that is below 100% of target (i.e., shortfall). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.